Study of the No-touch Saphenous Vein Graft

Launched by MESHALKIN RESEARCH INSTITUTE OF PATHOLOGY OF CIRCULATION · Feb 24, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new method of using a type of blood vessel called the saphenous vein to help improve blood flow in patients with coronary artery disease. The researchers want to see if a technique called "no-touch" saphenous vein grafting works better than the usual way of using the vein, which could lead to better results and less chance of the graft failing. The trial is currently looking for participants who need surgery for serious heart problems involving three major arteries.

To be eligible for this trial, you must have coronary artery disease and require surgery to improve blood flow to your heart. You will also need to give consent to participate. However, there are some criteria that might exclude you, such as having certain heart conditions, other serious health issues, or if you’ve had previous heart surgery. If you join the study, you will receive care and monitoring throughout the trial to ensure your safety and to help gather important information about the effectiveness of this new technique.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with coronary artery disease requiring three-vessel myocardial revascularization
• • Patient consent to the study
• Exclusion Criteria:
• • The diameter of the target arteries for conduits of the internal mammary arteries is less than 1 mm
• • Hemodynamically significant atherosclerosis of the subclavian arteries in the first segment
• • Stenosis of the right coronary artery less than 90%
• • Concomitant pathology requiring additional simultaneous surgical correction
• • Lack of IMA
• • COPD with FEV1 \<60%
• • BMI \>35
• • Prior heart surgery
• • Oncological diseases with a life expectancy of less than 5 years
• • ACS
• • CKD stage 4 and higher
• • The diameter of the SVG is less than 2 mm or its varicose expansion is more than 6 mm
• • CLTI IIb and more
• • Atherosclerosis of the brachiocephalic artery more than 50%